Answers

Government involved with health reform? Why not? - NewsOK.com

Government involved with health reform? Why not? NewsOK.com ... though, should be the potential for greater government involvement in the health care system. As we have seen with the $787 billion "stimulus” bill, ...

Conflict of interest exists between AARP, reform - Bowling Green Daily News

Visit Bulgaria

Conflict of interest exists between AARP, reform Bowling Green Daily News Our government gave a $18 million stimulus to AARP. Of course, the United Health Care Insurance Co. pays fees to AARP and its affiliates to promote its ... An Unhealthy Government Track Record Do what is right and pass health care bill 'Show me' first, Claire  - -

In health care debate, both sides being heard - Boston Globe

Globe and Mail

In health care debate, both sides being heard Boston Globe (Alex Brandon/ Associated Press) WASHINGTON - President Obama's top aides met frequently with lobbyists and health care industry heavyweights as his ... Ignagni, Tauzin Visited White House During Debate Time for Obama to Get His Priorities in Order Who Visited The White House (And Why You Should Care)

Virdante Pharmaceuticals, Inc.: Series A $30M

Virdante Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on increasing potency of plasma-derived intravenous immune globulin for the treatment of inflammation and autoimmune disease, closed a $30M Series A financing. Participants include Thomas, McNerney & Partners, Osage Partners, Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures.

Quinnova Pharmaceuticals, Inc.: Series B $17.4M

Quinnova Pharmaceuticals (Newtown, PA) a commercial-stage specialty biopharma company focused on dermatological drug reformulations and foam delivery systems, closed a $17.4M Series B financing. Participants include Safeguard Scientifics, Thomas, McNerney & Partners, H.I.G. Ventures.

Activaero, GmbH: Series A $15.9M

Activaero (Germany) a commercial-stage medical device company focused on patient-tailored controlled breathing and inhaled therapeutic delivery systems, closed a $15.9M Series A financing. Participants include BioMedPartners, VI Partners, Abalis Finance and Vesalius Biocapital.

3Q09 OnBioVC | Trend Analysis Now Available

Hot off the press! The 3Q09 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $1,663M flowed into early-stage biopharma, diagnostic and device companies in the third quarter of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who you [...]

September 2009 OnBioVC | Trend Analysis Now Available

Hot off the press! The September 2009 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $465M flowed into early-stage biopharma, diagnostic and device companies in the ninth month of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who [...]